To market, to market - 1995

[51] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1 (HIV-1) INHIBITORY INTERACTIONS BETWEEN PROTEASE INHIBITOR RO 31-8959 AND ZIDOVUDINE, 2',3'-DIDEOXYCYTIDINE, OR RECOMBINANT INTERFERON-ALPHA-A AGAINST ZIDOVUDINE-SENSITIVE OR ZIDOVUDINE-RESISTANT HIV-1 INVITRO [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (05) : 1143 - 1146

[52] PROTECTIVE EFFECT OF RIMEXOLONE ON CARTILAGE DAMAGE IN ARTHRITIC MICE - A COMPARATIVE-STUDY WITH TRIAMCINOLONE HEXACETONIDE [J]. AGENTS AND ACTIONS, 1990, 31 (1-2): : 135 - 142

[53] EVALUATION OF A PROLONGED INFUSION OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (DUTEPLASE) IN PREVENTING REOCCLUSION FOLLOWING SUCCESSFUL THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (14) : 1120 - 1127

[54] MYOCARDIAL INFARCT ARTERY PATENCY AND REOCCLUSION RATES AFTER TREATMENT WITH DUTEPLASE AT THE DOSE USED IN THE INTERNATIONAL STUDY OF INFARCT SURVIVAL-3 [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (05) : 386 - 392

[55] SUPPRESSIVE EFFECTS OF IPD-1151T (SUPLATAST-TOSILATE) ON INDUCTION OF MAST-CELLS FROM NORMAL MOUSE SPLENOCYTES [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 259 (01) : 15 - 20

[56] KONTOGHIORGHES GJ, 1990, ANN NY ACAD SCI, V612, P339

[57] KOTNOGHIORGHES GJ, 1995, ANALYST, V120, P845

[58] KUROKAWA T, 1994, BIOL PHARM BULL, V17, P383

[59] LAVELLE F, 1995, SEMIN ONCOL, V22, P3

[60] LINEBERGER CK, 1994, ANESTHESIOL CLIN N A, V12, P65

[51] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1 (HIV-1) INHIBITORY INTERACTIONS BETWEEN PROTEASE INHIBITOR RO 31-8959 AND ZIDOVUDINE, 2',3'-DIDEOXYCYTIDINE, OR RECOMBINANT INTERFERON-ALPHA-A AGAINST ZIDOVUDINE-SENSITIVE OR ZIDOVUDINE-RESISTANT HIV-1 INVITRO [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (05) : 1143 - 1146

[52] PROTECTIVE EFFECT OF RIMEXOLONE ON CARTILAGE DAMAGE IN ARTHRITIC MICE - A COMPARATIVE-STUDY WITH TRIAMCINOLONE HEXACETONIDE [J]. AGENTS AND ACTIONS, 1990, 31 (1-2): : 135 - 142

[53] EVALUATION OF A PROLONGED INFUSION OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (DUTEPLASE) IN PREVENTING REOCCLUSION FOLLOWING SUCCESSFUL THROMBOLYSIS IN ACUTE MYOCARDIAL-INFARCTION [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (14) : 1120 - 1127

[54] MYOCARDIAL INFARCT ARTERY PATENCY AND REOCCLUSION RATES AFTER TREATMENT WITH DUTEPLASE AT THE DOSE USED IN THE INTERNATIONAL STUDY OF INFARCT SURVIVAL-3 [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (05) : 386 - 392

[55] SUPPRESSIVE EFFECTS OF IPD-1151T (SUPLATAST-TOSILATE) ON INDUCTION OF MAST-CELLS FROM NORMAL MOUSE SPLENOCYTES [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 259 (01) : 15 - 20

[56] KONTOGHIORGHES GJ, 1990, ANN NY ACAD SCI, V612, P339

[57] KOTNOGHIORGHES GJ, 1995, ANALYST, V120, P845

[58] KUROKAWA T, 1994, BIOL PHARM BULL, V17, P383

[59] LAVELLE F, 1995, SEMIN ONCOL, V22, P3

[60] LINEBERGER CK, 1994, ANESTHESIOL CLIN N A, V12, P65